Every BGX vial is linked directly to a Certificate of Analysis
But a new Japanese study is pushing back on that narrative and its implications are important for policy, regulation, and industry credibility
The concept of "best time to apply" becomes less about pharmacokinetic optimization and more about practical convenience and skin site rotation
or Appears on the 503A bulks list or 503A Category 1 Bulk Drug Substances Under Evaluation list (i.e., the interim 503A bulks list) provided by the FDA if requirements one or two are not met *note that the FDAs position is that specifically refers to USP/NF drug monographs, not dietary supplement monographs 503B outsourcing facilities are even further restricted in their allowed bulk materials and may not compound a drug product unless the relevant bulk drug product, in addition to being accompanied by a valid CoA and manufactured in an FDA registered facility, meets one of the below requirements: Appears on the list identifying bulk drug substances for which there is a clinical need (503B bulks list or 503B Category1: Bulk Drug Substances Under Evaluation (i.e., the interim 503B bulks list)
1 Comparison between 15 model-designed compounds and the training data
How does this supplement support skin health